These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 20373861)
1. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. Altieri DC Future Oncol; 2010 Apr; 6(4):487-9. PubMed ID: 20373861 [No Abstract] [Full Text] [Related]
2. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951 [TBL] [Abstract][Full Text] [Related]
3. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Kang BH; Altieri DC Oncogene; 2009 Oct; 28(42):3681-8. PubMed ID: 19648961 [TBL] [Abstract][Full Text] [Related]
4. Advances in the role of heat shock protein 90 in prostate cancer. Fu Z; Jia B Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667 [TBL] [Abstract][Full Text] [Related]
5. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822 [TBL] [Abstract][Full Text] [Related]
6. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Moses MA; Henry EC; Ricke WA; Gasiewicz TA Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133 [TBL] [Abstract][Full Text] [Related]
7. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743 [TBL] [Abstract][Full Text] [Related]
8. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Ischia J; Saad F; Gleave M Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? Siegelin MD Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257 [TBL] [Abstract][Full Text] [Related]
10. 2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: rational identification of a new anticancer lead. Dutta Gupta S; Revathi B; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM Bioorg Chem; 2015 Apr; 59():97-105. PubMed ID: 25727264 [TBL] [Abstract][Full Text] [Related]
11. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342 [TBL] [Abstract][Full Text] [Related]
12. HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy. Condelli V; Crispo F; Pietrafesa M; Lettini G; Matassa DS; Esposito F; Landriscina M; Maddalena F Cells; 2019 Jun; 8(6):. PubMed ID: 31163702 [TBL] [Abstract][Full Text] [Related]
13. TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors. Kang BH BMB Rep; 2012 Jan; 45(1):1-6. PubMed ID: 22281005 [TBL] [Abstract][Full Text] [Related]
14. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949 [TBL] [Abstract][Full Text] [Related]
15. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells. Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK Cells; 2020 Mar; 9(3):. PubMed ID: 32204513 [TBL] [Abstract][Full Text] [Related]
16. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Nepali K; Lin MH; Chao MW; Peng SJ; Hsu KC; Eight Lin T; Chen MC; Lai MJ; Pan SL; Liou JP Bioorg Chem; 2019 Oct; 91():103119. PubMed ID: 31349117 [TBL] [Abstract][Full Text] [Related]
17. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer. Dutta Gupta S; Bommaka MK; Banerjee A Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095 [TBL] [Abstract][Full Text] [Related]
18. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach. Gupta SD; Swapanthi PS; Bhagya D; Federicci F; Mazaira GI; Galigniana MD; Subrahmanyam CVS; Gowrishankar NL; Raghavendra NM Anticancer Agents Med Chem; 2020; 20(3):369-385. PubMed ID: 31713499 [TBL] [Abstract][Full Text] [Related]
19. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action. Bickel D; Gohlke H Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378 [TBL] [Abstract][Full Text] [Related]